Sanofi Extends Cancer Ambitions With IL-2 Drug And Keytruda Combination

Seeking Cancer Blockbuster To Match Dupixent Success

Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.

Sanofi_Berlin
Dupixent is helping to power the new Sanofi, but the company wants to become a major player in oncology as well.

Sanofi is to work with Merck & Co. to study its interleukin-2 candidate in combination with immunotherapy blockbuster Keytruda in patients with various cancers.

The drug, named THOR-707, is the lead asset from Synthorx, the San Diego-based immuno-oncology company it acquired last December for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip